Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

Biochemical Pharmacology

Volumn 57, Issue 8, 1999, Pages 917-925

  Discafani, Carolyn M ^a   Carroll, Marion L ^a   Floyd Jr , M Brawner ^a   Hollander, Irwin J ^a   Johnson, Bernard D ^a   Kitchen, Douglas ^a   May, Michael K ^a   Malo, Madhu S ^a   Minnick Jr , Albert A ^a   Nilakantan, Ramaswamy ^a   Shen, Ru ^a   Wang, Yu Fen ^a   Wissner, Allan ^a   Greenberger, Lee M ^a  

^a PFIZER INC   (United States)

Author keywords

Anticancer; c erbB 2; Covalent inhibitor; Epidermal growth factor receptor; Tumor; Tyrosine kinase

Indexed keywords

CL 387785; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; ENZYME INHIBITION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOLECULAR MODEL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0033561601     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00356-6     Document Type: Article

References (31)

1. Prigent S., Lemoine N.R. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 4:1992;1-24.
2. Pawson T., Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science. 278:1997;2075-2080.
3. Gullick W.J. Prevalence of aberrant expression of epidermal growth factor receptor in human cancers. Br Med Bull. 47:1991;87-98.
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer Correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
5. Baselga J., Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 64:1994;127-154.
6. Lydon N.B., Mett H., Mueller M., Becker M., Cozens R.M., Stover D., Daniels D., Traxler P., Buchdunger E. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int J Cancer. 76:1998;154-163.
7. Levitzki A., Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science. 267:1995;1782-1788.
8. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
9. Ward W.H.J., Cook P.N., Slater A.M., Davies H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol. 48:1994;659-666.
10. Osherov N., Levitzki A. Epidermal growth factor-dependent activation of the src-family kinases. Eur J Biochem. 225:1994;1047-1053.
11. Traxler P., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of EGF-R. J Pharm Belg. 52:1997;88-96.
12. Kunkel M.W., Hook K.E., Howard C.T., Przybranowski S., Roberts B.J., Elliott W.L., Leopold W.R. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 13:1996;295-302.
13. Yoneda T., Lyall R.M., Alsina M.M., Persons P.E., Spada A.P., Levitski A., Zilberstein A., Mundy G.R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51:1991;4430-4435.
14. McLeod H.L., Brunton V.G., Eckardt N., Lear M.J., Robins D.J., Workman P., Graham M.A. In vivo pharmacology and anti-tumor evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer. 74:1996;1714-1718.
15. Wissner A, Johnson BD, Floyd MB and Kitchen DB, 4-Aminoquinazolines EGFR Inhibitors. US Patent 5,760,041, Jun. 2, 1998.
16. Carr R.M., Cable K.M., Wells G.N., Sutherland D.R. A convenient method for cyanation of aromatic iodo compounds. J Labelled Compd Radiopharm. 34:1994;887-897.
17. Knighton D.R., Zheng J., Eyck L.F.T., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 253:1991;407-411.
18. Knighton D.R., Cadena D.L., Zheng J., Ten Eyck L.F., Taylor S.S., Sowadski J.M., Gill G.N. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor kinase. Proc Natl Acad Sci USA. 90:1993;5001-5005.
19. Ullrich A., Coussens L., Hayflick S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J., Downward A.W., Mayes L.V., Whittle N., Waterfield M.D., Seeburg P.H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
20. Lothstein L., Hsu S.-I.H., Horwitz S.B., Greenberger L.M. Alternate overexpression of two P-glycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem. 264:1989;16054-16058.
21. Skehan P., Stornet R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J., Bokbosch H., Kenny S., Boyd M. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
22. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.D., Denny W.A. Tyrosine kinase inhibitors. 11. Soluble analogs of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biologic evaluation, and modeling of the mode of binding. J Med Chem. 40:1997;1519-1529.
23. Bacus S.S., Zelnick C.R., Plowman G., Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancer. Implication for tumor biology and clinical behavior. Am J Clin Pathol. 102:1994;S13-S24.
24. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., Shepard H.M. Differential responses of human tumor lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 37:1993;255-263.
25. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1987;178-182.
26. Telford W.G., King L.E., Fraker P.J. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif. 24:1991;447-459.
27. Hanks S.K., Hunter T. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J. 9:1995;576-596.
28. Plowman G.D., Ullrich A., Shawer L.K. Receptor tyrosine kinases as targets for drug intervention. Drug News Perspect. 7:1994;334-339.
29. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., Dobrusin E.M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA. 95:1998;12022-12027.
30. Bos M., Mendelsohn J., Kim Y.-M., Albanell J., Fry D.W., Baselga J. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 3:1997;2099-2106.
31. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Bowman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848.